Immunotherapy for prostate cancer: Is prostate an immune responsive tumor?

Current Opinion in Urology

Volumn 26, Issue 6, 2016, Pages 529-534

  Slovin, Susan F ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Antibodies; Immunotherapy; Prostate cancer; Sipuleucel T; Vaccines

Indexed keywords

IMMUNOLOGIC AGENT; CANCER VACCINE;

CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; HUMAN; IMMUNOGENICITY; INFLAMMATORY CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; IMMUNOLOGY; IMMUNOTHERAPY; MALE; PROSTATE TUMOR;

CANCER VACCINES; HUMANS; IMMUNOTHERAPY; MALE; PROSTATIC NEOPLASMS;

EID: 84983071831     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0000000000000334     Document Type: Review

References (26)

1. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-422.
2. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. New Engl J Med 2010; 363:711-723.
3. Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16:375-384.
4. Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016; 387:1909-1920.
5. Vivier E, Tomasello E, Baratin M, et al. Functions of natural killer cells. Nat Immunol 2008; 9:503-510.
6. Carrega P, Morandi B, Costa R, et al. Natural killer cells infiltrating human nonsmall-cell lung cancer are enrichedinCD56 bright CD16(-) cells and display an impaired capability to kill tumor cells. Cancer 2008; 112:863-875.
7. Mamessier E, Sylvain A, Thibult ML, et al. Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest 2011; 121:3609-3622.
8. Arnon TI, Markel G, Bar-Ilan A, et al. Harnessing soluble NK cell killer receptors for the generation of novel cancer immune therapy. PLoS One 2008; 3:e2150.
9. Gannon PO, Poisson AO, Delvoye N, et al. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods 2009; 348:9-17.
10. Pasero C, Gravis G, Guerin M, et al. Inherent and tumor-driven immune tolerance in the prostate microenvironment impairs natural kill cell antitumor activity. Cancer Res 2016; 76:2153-2165.
11. Bhavsar NA, Bream JH, Meeker AK, et al. A peripheral circulating TH1 cytokine profile is inversely associated with prostate cancer risk in CLUE II. Cancer Epidemiol Biomarkers Prev 2014; 23:2561-2567.
12. Winchester DA, Till C, Goodman PJ, et al. Variation in genes involved in the immune response and prostate cancer risk in the placebo arm of the Prostate Cancer Prevention Trial. Prostate 2015; 75:1403-1418.
13. McNeel DG, Nguyen LD, Ellis WJ, et al. Naturally occurring prostate cancer antigen-specific T cell responses of a Th1 phenotype can be detected in patients with prostate cancer. Prostate 2001; 47:222-229.
14. Idorn M, Køllgaard T, Kongsted P, et al. Correlation between frequencies of blood monocytic myeloid-derived suppressor cells, regulatory T cells and negative prognostic markers in patients with castration-resistant metastatic prostate cancer. Cancer Immunol Immunother 2014; 63:1177-1187.
15. Weide B, Martens A, Zelba H, et al. Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1-or Melan-A-specific T cells. Clin Cancer Res 2014; 20:1601-1609.
16. Davidsson S, Ohlson AL, Andersson SO, et al. CD4 helper T cells, CD8 cytotoxic T cells, and FOXP3(+) regulatory T cells with respect to lethal prostate cancer. Mod Pathol 2013; 26:448-455.
17. Barrack ER. TGF beta in prostate cancer: a growth inhibitor that can enhance tumorigenicity. Prostate 1997; 31:61-70.
18. Jakowlew SB. Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev 2006; 25:435-457.
19. Gameiro SR, Jammeh ML, Wattenberg MM, et al. Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. Oncotarget 2014; 5:403-416.
20. Gameiro SR, Malamas AS, Bernstein MB, et al. Tumor cells surviving exposure to proton or photon radiation share a common immunogenic modulation signature, rendering them more sensitive to T cell-mediated killing. Int J Rad Oncol 2016; 95:120-130.
21. Ardiani A, Farsaci B, Rogers CJ, et al. Combinationtherapy withasecond-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model. Clin Cancer Res 2013; 19:1-14.
22. Kwilas AF, Gameiro SF, Kim PS, et al. Improving clinical benefit for prostate cancer patients through the combination of androgen deprivation and immunotherapy. Oncoimmunology 2015; 4:61-63.
23. Sheikh NA, Jones LA. CD54 is a surrogate marker of antigen presenting cell activation. Cancer Immunol Immunother 2008; 57: 1381-1390.
24. Slovin SF, Higano CS, Hamid O, et al. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Ann Oncol 2013; 24: 1813-1821.
25. Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multi-centre, randomised, double-blind, phase 3 trial. Lancet Oncol 2014; 15: 700-712.
26. Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013; 499: 214-218.